Conclusion: GPRC5A may act as an oncogene in the progression of PaCa and could be a prognostic biomarker in predicting survival of PaCa. This evidence concerns the gene GPRC5A and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.